Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth

Bausch + Lomb Corporation (NYSE:BLCO) is one of the best Canadian stocks to buy under $20. On February 18, Bausch + Lomb reported record financial results for Q4 2025, with revenue rising 7% to $1.405 billion and adjusted EBITDA growing 27% to $330 million. This brought full-year revenue to $5.101 billion, driven by strong gains across its diversified portfolio. The company’s pharmaceutical segment led the way with 14% quarterly growth, while the Vision Care division, led by an 8% increase in contact lens sales, remained the largest contributor at $778 million for the quarter.

The standout performer of the year was the dry eye treatment Miebo, which saw Q4 revenue surge 111% to $112 million. Management attributed this success to marketing investments and a high-performing field force, noting that the product is on a clear trajectory toward profitability despite seasonal fluctuations. The surgical segment also showed resilience, achieving 20% growth in premium intraocular lenses/IOL as the company continued to recover from a voluntary product recall earlier in the year.

Looking ahead to 2026, the company is focusing on operational execution and financial discipline to maintain its 23.5% adjusted EBITDA margin. While facing competitive pressures in the IOL and contact lens markets, Bausch + Lomb expects its daily SiHy lenses to continue outperforming the global market. Additionally, the pharmaceutical segment is poised for further growth as the company stabilizes net pricing for Xiidra, forecasting mid-single-digit sales growth for that treatment in the coming year.

Bausch + Lomb Corporation (NYSE:BLCO) is an eye health company in the US, Puerto Rico, China, France, Japan, Germany, the UK, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.

While we acknowledge the potential of BLCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.